Last reviewed · How we verify

Anesthesia induction with remimazolam

Daegu Catholic University Medical Center · Phase 3 active Small molecule

Remimazolam is a benzodiazepine that enhances GABAergic neurotransmission by binding to GABA-A receptors, producing rapid sedation and anesthesia induction.

Remimazolam is a benzodiazepine that enhances GABAergic neurotransmission by binding to GABA-A receptors, producing rapid sedation and anesthesia induction. Used for Induction of general anesthesia in adults.

At a glance

Generic nameAnesthesia induction with remimazolam
SponsorDaegu Catholic University Medical Center
Drug classBenzodiazepine
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

Remimazolam is an ultra-short-acting benzodiazepine ester prodrug that is rapidly metabolized by non-specific esterases in the blood and tissues, allowing for quick onset and offset of action. It binds allosterically to GABA-A receptors in the central nervous system, potentiating inhibitory GABAergic signaling to produce sedation, anxiolysis, and anesthesia. Its ester structure and rapid metabolism distinguish it from longer-acting benzodiazepines, making it suitable for induction of general anesthesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: